Investing in Dividend Stocks: A Focus on Stability and Growth
When investing in dividend stocks, it’s crucial to focus on more than just the yield. While attractive, a high yield can sometimes mask underlying issues within a company. Investors should prioritize companies with solid operations and consistent payout increases. This article examines two notable players in the healthcare sector: AbbVie and Gilead Sciences. Both companies represent what income investors should seek for long-term stability and growth.
Why Look Beyond Yield?
Many investors are initially drawn to stocks with impressive dividend yields, but it’s vital to consider the sustainability of those dividends. Companies that successfully navigate market fluctuations while maintaining strong financial health are better positioned to reward shareholders over the long haul. This is where companies like AbbVie and Gilead Sciences shine.
1. AbbVie: A Dividend King
AbbVie is a standout choice for income investors and holds the prestigious title of Dividend King, having raised its payouts for an impressive 53 consecutive years. This streak includes the period when AbbVie was part of Abbott Laboratories, further showcasing its resilience and commitment to rewarding shareholders.
Solid Pharmaceutical Pipeline
As a pharmaceutical giant, AbbVie specializes in various therapeutic areas, particularly immunology. The company is well-known for its top-selling drugs, Skyrizi and Rinvoq, both of which have exceeded management’s expectations regarding sales growth. After losing patent exclusivity for its previous blockbuster, Humira, AbbVie demonstrated its strong recovery capabilities, turning an unexpected profit earlier than anticipated.
Financial Resilience
The company recently revised its revenue expectations for Skyrizi and Rinvoq, increasing its combined 2027 guidance to more than $31 billion—a jump from the previous estimate of approximately $27 billion. This growth, alongside AbbVie’s diverse lineup of other medications, showcases its ability to thrive beyond a single product. Additionally, AbbVie’s success in managing patent expirations, such as that of Humira, speaks volumes about its underlying business durability.
Impressive Dividend Yield
With a forward yield exceeding 3.5%, AbbVie’s dividend payments outpace the S&P 500 average of 1.3%. This makes it an attractive option for income-seeking investors who value reliability and growth.
2. Gilead Sciences: Innovating for the Future
Gilead Sciences is another formidable player in the pharmaceutical landscape, particularly in the HIV sector, where it maintains a dominant position. The company’s focus on innovation has helped it carve a niche in the healthcare industry.
Stable yet Diversifying Portfolio
Despite facing challenges, Gilead’s HIV division saw a 6% year-over-year revenue increase, totaling $4.6 billion. Its flagship product, Biktarvy, is the most prescribed HIV regimen in the U.S., and Descovy for PrEP remains a leading option.
However, Gilead recognizes the need for diversification. Its involvement in developing Veklury, the first COVID-19 treatment to earn FDA approval, showcases the company’s adaptability. While sales from Veklury have fluctuated, it has positively impacted Gilead’s overall revenue, reinforcing the company’s financial stability.
Growth in Oncology
Gilead is also pushing into oncology, with over a third of its 58 pipeline programs focused in this area. This strategic focus not only mitigates risks associated with dependence on its HIV portfolio but also positions the company for further growth.
Strong Dividend Growth
With a forward yield of 3.2%, Gilead’s dividends have surged nearly 84% over the past decade. This growth reinforces Gilead’s commitment to returning capital to shareholders, making it a solid consideration for long-term investors who prioritize income.
A Focus on the Future
Both AbbVie and Gilead Sciences exemplify the qualities that long-term investors should seek in dividend stocks. With their impressive growth potential, solid operational foundation, and commitment to shareholder returns, these companies represent attractive opportunities for income-focused investors looking to build a stable portfolio.
As you consider your investment strategy, remember that the right dividend stocks extend beyond yield to include robust business models and the potential for continued payout growth.
